DEPOCYT 10 MG
CYTARABINE : 10 MG · DIN 02241150 · SKYEPHARMA INC.
Health Canada status: CANCELLED POST MARKET
What is DEPOCYT?
DEPOCYT 10 MG contains CYTARABINE : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02241150, held by SKYEPHARMA INC., supplied as SUSPENSION for INTRATHECAL administration. Health Canada currently lists it as cancelled post market, status dated 29-Jun-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What else is DEPOCYT called?
The same molecule, CYTARABINE, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| ARACYTINE | Latin | Morocco |
| ALEXAN | Latin | Czechia |
| CYTARABINE ACCORD | Latin | Czechia |
| CYTARABINE EBEWE | Latin | Morocco |
| Pfizer Australia Pty Ltd | Latin | Australia |
| VYXEOS LIPOSOMAL | Latin | Czechia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02241150 |
|---|---|
| Brand name | DEPOCYT |
| Generic / active ingredient | CYTARABINE : 10 MG |
| Manufacturer | SKYEPHARMA INC. |
| Strength | 10 MG |
| Dosage form | SUSPENSION |
| Route of administration | INTRATHECAL |
| Schedule | Prescription |
| ATC code | L01BC01 CYTARABINE |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 29-Jun-2017 |
| Original market date | 2000-12-29 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02241150 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2241150 |
| Brand name | DEPOCYT |
| Active ingredient / INN | CYTARABINE : 10 MG |
| ATC code | L01BC01 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L01 |
| AHFS class | 10:00.00 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | SKYEPHARMA INC. |
Which pack is which?
| Strength on the label | 10 MG |
|---|---|
| Dosage form | SUSPENSION |
| Route | INTRATHECAL |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Is CYTARABINE in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Anticipated — reported by PFIZER CANADA ULC (Tier 3 Drug Shortages About & Resources), last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code L01BC01 CYTARABINE. 3 of 19 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CYTARABINE INJECTION | 100 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02126656 |
| CYTARABINE INJECTION | 100 MG | SOLUTION | STERIMAX INC | MARKETED | DIN 02515296 |
| PMS-CYTARABINE | 100 MG | SOLUTION | PHARMASCIENCE INC | MARKETED | DIN 02406772 |
| AJ-CYTARABINE | 100 MG | SOLUTION | AGILA JAMP CANADA INC | CANCELLED PRE MARKET | DIN 02404397 |
| CYTARABINE - PWS 1GN/VIAL | 1 G | POWDER FOR SOLUTION | NOVOPHARM LIMITED | CANCELLED POST MARKET | DIN 02167883 |
| CYTARABINE - PWS 2GM/VIAL | 2 G | POWDER FOR SOLUTION | NOVOPHARM LIMITED | CANCELLED POST MARKET | DIN 02167891 |
| CYTARABINE - PWS 500MG/VIAL | 500 MG | POWDER FOR SOLUTION | NOVOPHARM LIMITED | CANCELLED POST MARKET | DIN 02167875 |
| CYTARABINE INJ 100MG/ML | 100 MG | LIQUID | DAVID BULL LABORATORIES (PTY) LTD. | CANCELLED POST MARKET | DIN 00885797 |
| CYTARABINE INJECTION BP | 100 MG | SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED PRE MARKET | DIN 02394901 |
| CYTARABINE INJECTION, MYLAN STD. | 100 MG | SOLUTION | MYLAN PHARMACEUTICALS ULC | CANCELLED PRE MARKET | DIN 02402203 |
Who else supplies CYTARABINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CYTARABINE appears in 30 registered pack listings across 6 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does CYTARABINE cost around the world?
CYTARABINE is listed on 7 national price registers Nexara tracks, across 42 pack listings published on 7 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| Saudi Arabia | public | 9 | 12 | 01 Sep 2026 |
| South Africa | single exit price | 10 | 10 | 01 Sep 2026 |
| Morocco | PPV (public price) | 2 | 7 | 05 Sep 2026 |
| Czechia | max producer price (ex-factory) | 3 | 5 | 03 Sep 2026 |
| United Kingdom | hospital | 5 | 5 | 31 Aug 2026 |
| Australia | ex-manufacturer | 1 | 2 | 08 Sep 2026 |
| Greece | producer price (ex-factory) | 1 | 1 | 03 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.